IRIS
PALMIERI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.791
AS - Asia 1.386
EU - Europa 1.301
SA - Sud America 256
AF - Africa 32
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.776
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.731
SG - Singapore 653
IT - Italia 635
CN - Cina 204
BR - Brasile 198
RU - Federazione Russa 186
HK - Hong Kong 173
VN - Vietnam 121
IE - Irlanda 93
DE - Germania 64
JP - Giappone 59
NL - Olanda 57
GB - Regno Unito 50
FR - Francia 49
IN - India 43
FI - Finlandia 42
CA - Canada 37
ID - Indonesia 22
PL - Polonia 21
AR - Argentina 20
SE - Svezia 19
ES - Italia 17
MX - Messico 17
KR - Corea 15
BD - Bangladesh 13
TH - Thailandia 13
AT - Austria 11
CO - Colombia 11
ZA - Sudafrica 11
BE - Belgio 10
IQ - Iraq 10
PH - Filippine 9
PK - Pakistan 9
VE - Venezuela 8
IR - Iran 7
SA - Arabia Saudita 7
AU - Australia 6
CZ - Repubblica Ceca 6
TR - Turchia 6
UA - Ucraina 6
EC - Ecuador 5
PY - Paraguay 5
GR - Grecia 4
HR - Croazia 4
KE - Kenya 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
TN - Tunisia 4
CL - Cile 3
DO - Repubblica Dominicana 3
EG - Egitto 3
LT - Lituania 3
LU - Lussemburgo 3
MY - Malesia 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CH - Svizzera 2
ET - Etiopia 2
GE - Georgia 2
IL - Israele 2
MA - Marocco 2
NP - Nepal 2
PS - Palestinian Territory 2
RO - Romania 2
SD - Sudan 2
TW - Taiwan 2
UY - Uruguay 2
UZ - Uzbekistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BG - Bulgaria 1
BY - Bielorussia 1
CM - Camerun 1
CR - Costa Rica 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
HU - Ungheria 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
SI - Slovenia 1
SR - Suriname 1
TT - Trinidad e Tobago 1
Totale 5.776
Salva come PNG Salva come JPEG
Città #
Singapore 394
Houston 336
Wilmington 330
San Jose 213
Rome 196
Hong Kong 167
Ashburn 153
Chandler 153
New York 110
Beijing 99
Dallas 94
Fairfield 91
Council Bluffs 78
Dublin 71
Los Angeles 59
Santa Clara 57
Tokyo 56
Engelhard 49
Milan 49
Ho Chi Minh City 45
Woodbridge 43
Medford 41
The Dalles 40
Ann Arbor 37
Seattle 35
Cambridge 33
Boardman 32
Buffalo 29
Moscow 26
Lauterbourg 23
North Bergen 23
Orem 21
São Paulo 21
Lawrence 20
Lappeenranta 19
Hanoi 18
Warsaw 18
Jakarta 17
Brooklyn 16
Helsinki 16
San Diego 16
Bologna 15
Creede 15
Seoul 15
Montreal 14
Munich 14
Nuremberg 13
Frankfurt am Main 12
Bang Bai Mai 11
Stockholm 11
Amsterdam 10
Chicago 10
Colorado Springs 10
London 10
Toronto 10
Brussels 9
Billings 8
Redondo Beach 8
Bari 7
Da Nang 7
Dearborn 7
Johannesburg 7
Phoenix 7
Turin 7
Atlanta 6
Baghdad 6
Bay Shore 6
Porto Alegre 6
Pune 6
Rio de Janeiro 6
Shenzhen 6
Biên Hòa 5
Brno 5
Chennai 5
Denver 5
Florence 5
Haiphong 5
Hyderabad 5
Marseille 5
Mexico City 5
Mumbai 5
Parma 5
Roebling 5
Tolentino 5
Washington 5
Asunción 4
Bari Sardo 4
Campinas 4
Castel Volturno 4
Charlotte 4
Garbagnate Milanese 4
Guangzhou 4
Jeddah 4
Lahore 4
Manchester 4
Manila 4
Modena 4
Nairobi 4
New Delhi 4
Olympia 4
Totale 3.753
Salva come PNG Salva come JPEG
Nome #
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 382
Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma 252
An evaluation of enasidenib for the treatment of acute myeloid leukemia 243
Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial 224
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness 218
WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine 215
ACUTE LEUKEMIA AND LATENT TUBERCULOSIS INFECTION IN ITALY: QUANTIFERON-TB TEST SCREENING IN A LOW TUBERCULOSIS INCIDENCE COUNTRY 197
The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma 197
Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin 191
FEVER OF UNKNOWN ORIGIN AND MULTIDRUG-RESISTANT ORGANISMS COLONIZATION IN AML PATIENTS 149
Current strategies for detection and approach to measurable residual disease in Acute Myeloid Leukemia 147
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 142
Vitamin C Deficiency in Patients With Acute Myeloid Leukemia 141
Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation 133
Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in {SARS}-{CoV}-2 infected patients: a single center study 130
The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia 128
Acute Leukemia diagnosis during the Covid-19 pandemic 128
A complex clinical presentation of ultra-high risk acute promyelocytic leukemia: A case report and insights on management 124
CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML 123
Use of Primary Prophylaxis with G-CSF in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy Does Not Affect Quality of Response 119
An Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone 108
Ponatinib and Risk of Thrombotic Events: In Vitro Study on Platelet Functions 106
CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia 103
Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients 101
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy 99
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML 98
Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience 96
A fatal case of peritonitis due to colonic localization of acute myeloid leukemia 88
Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy 87
Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis 85
Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations 82
Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia 80
Leukemia cutis in a patient with acute myeloid leukemia undergoing Azacitidine-Venetoclax: case presentation and review of the literature 78
Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia 75
In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia 75
The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19 75
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML) 74
Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia 74
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION 72
Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia 71
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias 66
Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms 63
Fitness in acute myeloid leukemia, state of the art and future directions 62
Editorial: Measurable residual disease in hematologic malignancies 60
Risk-adapted MRD-directed therapy for young acute myeloid leukemia adults: 6-year update of the GIMEMA AML1310 trial 57
Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis 55
Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy 53
FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET 50
The response to oxidative damage correlates with driver mutations and clinical outcome in patients with myelofibrosis 46
Measurable residual disease as an actionable biomarker in acute myeloid leukemia. Ready or not? 45
Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial 37
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 36
Real World Study on the Best CPX‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation 36
Incidence and Characteristics of Perianal Infections in CPX-351-Treated AML Patients 28
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia 27
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351 21
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 8
Allogeneic stem cell transplantation in patients with a prior history of prostate cancer 8
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML 8
APL‐like subset within NPM1‐mutated AML: A distinct immunophenotype correlating with early vascular complications 7
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm 7
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation 6
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts 6
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm 6
Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review 6
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 6
Totale 6.120
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.407
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.407
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202127 0 0 0 0 0 0 0 0 0 8 9 10
2021/2022325 4 11 13 3 9 45 16 17 52 31 20 104
2022/2023575 54 38 47 40 49 93 86 50 67 19 19 13
2023/2024532 26 8 168 9 20 103 17 45 30 16 20 70
2024/20251.239 48 168 114 75 25 78 132 62 195 113 138 91
2025/20262.522 238 127 324 241 335 107 301 318 277 254 0 0
Totale 6.120